RBC Capital analyst Brian Abrahams lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $55 but keeps an Outperform rating on the shares. Following ESMO updates, the potential $500M sales opportunity for ‘701 in HNSCC and $350M sales opportunity in cervical cancer have been better de-risked, the analyst tells investors in a research note. RBC adds that investors are still not fully appreciating Corbus’s potential large out-year sales opportunities across oncology and obesity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals: Promising Pipeline and Strategic Plans Justify Buy Rating
- Corbus Pharmaceuticals Advances Oncology and Obesity Pipeline
- Corbus Pharmaceuticals: Strong Financials and Promising Clinical Pipeline Drive Buy Rating
- Corbus Pharmaceuticals Completes $75 Million Public Offering
- Corbus Pharmaceuticals sees cash runway into 2028